Glycosan BioSystems, was based in Salt Lake City, Utah, where the company was founded by Glenn Prestwich, William Tew, and Anna Scott in January 2006. The company received startup support from the Centers of Excellence Program for innovative research in Utah and from the University of Utah, then closed its first round of investment in May 2007. Glycosan’s patent-pending Extracel™ technology was developed by the Center for Therapeutic Biomaterials at the University of Utah. Glycosan was acquired by BioTime, Inc. (Alameda, CA) in 2011 and continues its focus on manufacturing the highest-quality hydrogels for research and soon for clinical applications.
Intellectual Property
BioTime, Inc. holds exclusive worldwide rights to a patent estate, which was licensed from the University of Utah Research Foundation with broad claims to product chemical composition, method of crosslinking, method of preparation, and use of the synthetic extracellular matrix (sECM).
The exclusive sECM technology behind Glycosan’s Extracel® and HyStem® product lines makes several specific applications possible, including:
(Worldwide except the US):
All uses including in vivo medical devices but excluding animal therapeutics and animal health
(US only)
in vitro three-dimensional cell culture and in vitro medical devices
in vitro and in vivo animal models to screen for drug efficacy, safety, and toxicology
reagents for tissue and cell preservation
personal-care products
BioTime, Inc. also holds a co-exclusive license for tissue engineering and cell-therapy applications of Extracel and HyStem.
